New hope for brain cancer: Triple-Drug attack shows promise
NCT ID NCT07416890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) for people with a type of brain lymphoma that has come back or is hard to treat. The goal is to see if this mix can shrink tumors and help patients live longer. About 24 adults will take part, and those who respond may get a stem cell transplant or radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310058, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lifestyle choices after a stroke extend life and prevent a second one?
- What happens years after CAR-T therapy? a study aims to find out
- Can a targeted drug boost standard chemo for aggressive lymphoma?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Engineered immune cells take on tough lymphomas
- Promising drug may shrink brain tumors in relapsed lymphoma